RenovoRx (RNXT) Registration Filing summary

Company overview and business model

• Commercial and clinical stage life sciences company focused on targeted drug delivery for difficult-to-treat cancers, with a lead product combining intra-arterial gemcitabine delivery via the RenovoCath device.

• RenovoCath is FDA-cleared for local drug delivery and is being commercialized for standalone use, targeting high-volume cancer centers and leveraging organic demand.

• The company’s patented Trans-Arterial Micro-Perfusion (TAMP) platform aims to improve safety and efficacy by delivering chemotherapy directly to tumor sites, minimizing systemic toxicity.

• Holds 19 issued and 12 pending patents covering its technology, and is expanding its commercial and clinical pipeline to additional solid tumor indications.

Financial performance and metrics

• Revenue growth is being driven by sales of RenovoCath devices, with meaningful traction at academic and National Cancer Institute-designated centers.

• Initial U.S. addressable market for RenovoCath estimated at $400 million in peak annual sales, with potential for multi-billion dollar total addressable market as indications expand.

Use of proceeds and capital allocation

• Net proceeds from offerings will be used for working capital, continued progression of the Phase III TIGER-PaC study, and development and execution of commercial sales and marketing activities for RenovoCath.

• Management has broad discretion over allocation of proceeds, with investments in interest-bearing, investment-grade securities pending use.